New antibody drug HB0043 gets first human safety check

NCT ID NCT06999083

Completed Knowledge-focused Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the safety and tolerability of a single dose of HB0043, a lab-made antibody that targets two inflammatory proteins (IL-17A and IL-36R), in 52 healthy adults aged 18 to 55. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moved through the body. Since this is an early Phase 1 trial, it does not test whether the drug treats any disease—only that it is safe enough to study further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HB0043 (a bispecific antibody targeting IL-17A and IL-36R)
What this could lead to: If successful, this could pave the way for future studies of HB0043 in inflammatory diseases like psoriasis or arthritis.
What could go wrong: This is an early Phase 1 trial in healthy volunteers, so it only tests safety and dosing—not whether the drug works for any disease. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

New Zealand Clinical Research , Grafton, Auckland, 3 Ferncroft Street,

Auckland, Grafton, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.